Doris Makari

Aug 20, 2024 | cancernetwork.com | Adam Brufsky |Xianchen Liu |Benjamin Li |Lynn McRoy |Doris Makari |Rachel M. Layman | +2 more

BackgroundCardiovascular diseases (CVDs) can impact breast cancer treatment selection and clinical outcomes. A CDK4/6 inhibitor combined with endocrine therapy (ET) is now the standard of care as a first-line treatment for patients with hormone receptor–positive (HR+)/HER2-negative (HER2–) metastatic breast cancer. However, the effectiveness data of CDK4/6 inhibitors in patients with metastatic breast cancer and CVD are limited.

Jul 25, 2024 | cancernetwork.com | Heather Moore |Avirup Guha |Irene Arias |Stella Stergiopoulos |Benjamin Li |Michael G. Fradley | +3 more

BackgroundThe prevalence of preexisting cardiovascular (CV) comorbidities at diagnosis of hormone receptor-positive (HR+)/HER2-negative (HER2–) metastatic breast cancer (mBC) has not been well established. We aimed to describe the prevalence of preexisting CV comorbidities in patients with newly diagnosed HR+/HER2– mBC and to describe the first documented cancer treatment and concurrent medications with risk of QT interval (QTc) prolongation for patients with or without CV comorbidities.